Pricing

Panacea Acquisition Corp. (PANA.UN)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David T. Hung
Employees:
60
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO, CA, 94103
(415) 754-3517

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Nuvation Bio Inc. focuses on the development of therapeutic candidates for oncology. Lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. Company was formerly known as RePharmation Inc.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available